Tapentadol for acute and chronic pain

Expert Opinion on Pharmacotherapy

Volumn 11, Issue 11, 2010, Pages 1783-1785

  Sloan, Paul ^a  

^a UNIVERSITY OF KENTUCKY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

OXYCODONE; TAPENTADOL; MU OPIATE RECEPTOR; PHENOL DERIVATIVE;

ANALGESIC ACTIVITY; CHRONIC PAIN; CONSTIPATION; DRUG ELIMINATION; DRUG HALF LIFE; DRUG MECHANISM; EDITORIAL; GASTROINTESTINAL SYMPTOM; HUMAN; NAUSEA; PAIN; SUSTAINED DRUG RELEASE; TOOTH PAIN; VOMITING; ACUTE DISEASE; ANTAGONISTS AND INHIBITORS; CHRONIC DISEASE;

ACUTE DISEASE; CHRONIC DISEASE; HUMANS; PAIN; PHENOLS; RECEPTORS, OPIOID, MU;

EID: 77954771359     PISSN: 14656566     EISSN: None     Source Type: Journal    
DOI: 10.1517/14656566.2010.495870     Document Type: Editorial

References (16)

1. Sloan PA, Babul N. Extended-release opioids for the management of chronic non-malignant pain. Expert Opin Drug Deliv 2006;3:489-497
2. Chou R, Fanciullo GJ, Fine PG, et al. Clinical guidelines for the use of chronic opioid therapy in chronic noncancer pain. J Pain 2009;10:113-130
3. Sloan PA, Hamann SR. Ultra low-dose opioid antagonists to enhance opioid analgesia. J Opioid Manag 2006;2:295-304
4. Efficacy and safety of tapentadol extended release. Expert Opin Pharmacother 2010;11(11):1787-1804
5. Tzschentke TM, De Vry J, Terlinden R, et al. Tapentadol HCL. Drugs Future 2006;31:1053-1061
6. Hartrick CT. Tapentadol immediate release for the relief of moderate-to-severe acute pain. Expert Opin Pharmacother 2009;10:2687-2696
7. Wade WE, Spruill WJ. Tapentadol hydrochloride: a centrally acting oral analgesic. Clin Ther 2009;31:2804-2818
8. Terlinden R, Kogel BY, Englberger W, Tzschentke TM. In vitro and in vivo characterization of tapentadol metabolites. Methods Find Exp Clin Pharmacol 2010;32:31-38
9. Terlinden R, Ossig J, Fliegert F, et al. Absorption, metabolism, and excretion of 14C-labeled tapentadol HCL in healthy male subjects. Eur J Drug Metab Pharmacokinet 2007;32:163-169
10. Kleinert R, Lange C, Steup A, et al. Single dose analgesic efficacy of tapentadol in postsurgical dental pain: the results of a randomized, double-blind, placebo-controlled study. Anesth Analg 2008;107:2048-2055
11. Daniels SE, Upmalis D, Okamoto A, et al. A randomised, double-blind, phase III study comparing multiple doses of tapentadol IR, oxycodone IR, and placebo for postoperative (bunionectomy) pain. Curr Med Res Opin 2009;25:765-776
12. Hale M, Upmalis D, Okamoto A, et al. Tolerability of tapentadol immediate release in patients with lower back pain or osteoarthritis of the hip or knee over 90 days: a randomized, double-blind study. Curr Med Res Opin 2009;25:1095-1104
13. Pergolizzi J, Boger RH, Budd K, et al. Opioids and the management of chronic severe pain in the elderly: consensus statement of an International Expert Panel with focus on the six clinically most often used World Health Organization Step III opioids (buprenorphine, fentanyl, hydromorphone, methadone, morphine, oxycodone). Pain Pract 2008;8:287-313
14. Etropolski M, Shapiro A, Okamoto C, et al. Efficacy and safety of tapentadol ER for diabetic peripheral neuropathic pain: results of a randomized-withdrawal, double-blind, placebo-controlled phase III study. Neurology 2009;72:A217-8
15. Christoph T, De Vry J, Tzschentke TM. Tapentadol, but not morphine, selectively inhibits disease-related thermal hyperalgesia in a mouse model of diabetic neuropathic pain. Neuroscience Lett 2010;470:91-94
16. NUCYNTA(TM) (tapentadol) CII immediate release tablets now available for relief of moderate to severe acute pain ((2010). Available from: www.Nucynta.com /nucynta/dosing-and-administration.html [Accessed May 2010]